Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. (Q33339174)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Bernadeta Ceglarek

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

16

A Dmoszyńska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

13

A B Skotnicki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Beata Stella-Hołowiecka

12

object named as

B Stella-Hołowiecka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

Jadwiga Dwilewicz-Trojaczek

11 November 2019

5

object named as

J Dwilewicz-Trojaczek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1

T Robak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Kazimierz Kuliczkowski

10

object named as

K Kuliczkowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

11

D Wołowiec

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

J Z Błoński

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M Kasznicki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

P Boguradzki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

L Konopka

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

J Sułek

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

W Nowak

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

B Moskwa-Sroka

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M Calbecka

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

1510-1516

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Cytotoxicity of 2-chlorodeoxadenosine (cladribine, 2-cdA) in combination with other chemotherapy drugs against two lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Infectious and immunosuppressive complications of purine analog therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Management of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402216

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11587207%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 November 2019

1007333618

0 references

1 reference